LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials

SIMPLE SUMMARY: In the past few decades, targeted therapy and immunotherapy have transformed tremendously the chances of survival. Checkpoint inhibitors that block programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) pathways hold the most promise. However, more than half of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Bai-Wei, Zhang, Fei-Yang, Wang, Yun, Chen, Guo-Ming, Nie, Man, Zhao, Zhou-Kai, Chen, Xiao-Jiang, Jiang, Kai-Ming, Nie, Run-Cong, Chen, Ying-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599469/
https://www.ncbi.nlm.nih.gov/pubmed/36291763
http://dx.doi.org/10.3390/cancers14204975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599469/
https://www.ncbi.nlm.nih.gov/pubmed/36291763
http://dx.doi.org/10.3390/cancers14204975

Ejemplares similares